Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Molecular and Cellular Biochemistry Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Mol Med Rep. 2018 May;17(5):6585-6597. doi: 10.3892/mmr.2018.8716. Epub 2018 Mar 9.
Pathogenic fungi, including Candida glabrata, develop strategies to grow and survive both in vitro and in vivo under azole stress. However, the mechanisms by which yeast cells counteract the inhibitory effects of azoles are not completely understood. In the current study, it was demonstrated that the expression of the ergosterol biosynthetic genes ERG2, ERG3, ERG4, ERG10, and ERG11 was significantly upregulated in C. glabrata following fluconazole treatment. Inhibiting ergosterol biosynthesis using fluconazole also increased the expression of the sterol influx transporter AUS1 and the sterol metabolism regulators SUT1 and UPC2 in fungal cells. The microarray study quantified 35 genes with elevated mRNA levels, including AUS1, TIR3, UPC2, and 8 ERG genes, in a C. glabrata mutant strain lacking ERG1, indicating that sterol importing activity is increased to compensate for defective sterol biosynthesis in cells. Bioinformatic analyses further revealed that those differentially expressed genes were involved in multiple cellular processes and biological functions, such as sterol biosynthesis, lipid localization, and sterol transport. Finally, to assess whether sterol uptake affects yeast susceptibility to azoles, we generated a C. glabrata aus1∆ mutant strain. It was shown that loss of Aus1p in C. glabrata sensitized the pathogen to azoles and enhanced the efficacy of drug exposure under low oxygen tension. In contrast, the presence of exogenous cholesterol or ergosterol in medium rendered the C. glabrata AUS1 wild‑type strain highly resistant to fluconazole and voriconazole, suggesting that the sterol importing mechanism is augmented when ergosterol biosynthesis is suppressed in the cell, thus allowing C. glabrata to survive under azole pressure. On the basis of these results, it was concluded that sterol uptake and sterol biosynthesis may act coordinately and collaboratively to sustain growth and to mediate antifungal resistance in C. glabrata through dynamic gene expression in response to azole stress and environmental challenges.
致病真菌,包括光滑念珠菌,在唑类药物压力下,无论是在体外还是体内,都会发展出生长和存活的策略。然而,酵母细胞对抗唑类药物抑制作用的机制尚不完全清楚。在本研究中,研究表明氟康唑处理后,光滑念珠菌中甾醇生物合成基因 ERG2、ERG3、ERG4、ERG10 和 ERG11 的表达显著上调。用氟康唑抑制甾醇生物合成也会增加真菌细胞中甾醇摄取转运蛋白 AUS1 和甾醇代谢调节剂 SUT1 和 UPC2 的表达。微阵列研究量化了 35 个 mRNA 水平升高的基因,包括 AUS1、TIR3、UPC2 和 8 个 ERG 基因,在缺乏 ERG1 的光滑念珠菌突变株中,表明甾醇摄取活性增加以补偿细胞中缺陷的甾醇生物合成。生物信息学分析进一步表明,这些差异表达的基因参与了多个细胞过程和生物学功能,如甾醇生物合成、脂质定位和甾醇转运。最后,为了评估甾醇摄取是否影响酵母对唑类药物的敏感性,我们生成了光滑念珠菌 aus1∆突变株。结果表明,缺失 C. glabrata 的 Aus1p 使病原体对唑类药物敏感,并在低氧张力下增强药物暴露的疗效。相比之下,培养基中存在外源性胆固醇或麦角固醇使 C. glabrata AUS1 野生型菌株对氟康唑和伏立康唑高度耐药,表明当细胞中麦角固醇生物合成受到抑制时,甾醇摄取机制增强,从而使 C. glabrata 在唑类药物压力下存活。基于这些结果,可以得出结论,甾醇摄取和甾醇生物合成可能通过唑类药物应激和环境挑战下的动态基因表达,协调合作以维持生长并介导光滑念珠菌的抗真菌耐药性。